Press Release: C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D.
Express News | C4 Therapeutics Appoints Paige Mahaney, Ph.d., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.d.
Express News | C4 Therapeutics Announces Presentations and Participation in 7TH Annual Targeted Protein Degradation & Induced Proximity Summit
C4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity Summit
C4 Therapeutics, Inc.'s (NASDAQ:CCCC) Business Is Trailing The Industry But Its Shares Aren't
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Express News | C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Stifel Nicolaus Keeps Their Buy Rating on C4 Therapeutics (CCCC)
Morgan Stanley Maintains C4 Therapeutics(CCCC.US) With Hold Rating, Maintains Target Price $8
Express News | C4 Therapeutics Inc : Evercore ISI Raises Target Price to $10 From $9
Hold Rating on C4 Therapeutics Amid Early-Stage Drug Development and Market Caution
C4 Therapeutics Says Protein Degrader Candidate 'Well-Tolerated' in Early Phase 1 Data
Express News | C4 Therapeutics Inc - Cft1946 Well-Tolerated at All Dose Levels; No Dose-Limiting Toxicities
C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024
C4 Therapeutics Announces Delivery of Second Development Candidate to Biogen
Methanex, Merck And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Top Premarket Decliners
Express News | C4 Therapeutics Shares Are Trading Lower. The Company Announced the Abstract Sharing Clinical Data From Its Ongoing Phase 1 Clinical Trial of CFT1946 in Mutant BRAF V600 Solid Tumors, Was Released in Conjunction With the ESMO Congress 2024
C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024
Stifel Maintains C4 Therapeutics(CCCC.US) With Buy Rating, Maintains Target Price $14